Xenonics Reports Third Quarter Results

CARLSBAD, Calif.--()--XENONICS HOLDINGS, INC. (OTCBB:XNNH) (OTCQB:XNNH) today announced financial results for the third quarter and first nine months of fiscal 2012.

Revenue for the three months ended June 30, 2012 was $403,000. This compares to revenue of $775,000 for the third quarter of fiscal 2011. The net loss for the third quarter of fiscal 2012 was $630,000, or $0.03 per share. This compares to a net loss for the third quarter of fiscal 2011 of $597,000, or $0.02 per share.

Selling, general and administrative expenses decreased 12% to $527,000 for this year's third quarter compared to $601,000 for the same period last year. Research and development expenses decreased to $191,000 for this year's third quarter compared to $198,000 a year ago.

For the nine months ended June 30, 2012, revenue was $1,200,000 compared to $6,323,000 for the first nine months of fiscal 2011. The net loss for the first nine months of fiscal 2012 was $1,857,000, or $0.07 per share. This compares to net income for the first nine months of fiscal 2011 of $377,000, or $0.02 per share. SG&A decreased 15% to $1,587,000 compared to $1,878,000 for last year's first nine months.

At June 30, 2012, Xenonics reported working capital of $893,000, and a current ratio of 1.4-to-1.

"Our defense markets remained sluggish in the third fiscal quarter and we experienced further delays in the receipt of several substantial, funded orders. However, the military business appears to be improving and the Company received approximately $1,000,000 in new military purchase orders in the current quarter and we have shipped over $700,000 of these orders, including an order for 200 SuperVision units for the US Army Military Police. This is the first significant order for SuperVision placed by the US Military. Our inventory is in excess of $2,000,000 in anticipation of the receipt of large funded military orders which are working their way through the procurement process", said Chairman Alan Magerman.

Conference Call

Xenonics has scheduled a conference call at 11:00 a.m. EDT this morning to discuss its results for fiscal 2012. The dial-in number is (800) 638-4930 and the passcode is #44638557. A simultaneous webcast of the conference call can be accessed from the Webcast Center of the Investor Relations link at www.xenonics.com. A replay will be available after 1:00 p.m. EDT at this same Internet address. For a telephone replay, dial (888) 286-8010, passcode #76744701, after 1:00 p.m. EDT.

About Xenonics

Xenonics Holdings, Inc. develops and produces advanced, lightweight and compact ultra-high-intensity illumination and low-light vision products for military, law enforcement, public safety, and commercial and private sector applications. Xenonics' NightHunter line of illumination products is used by every branch of the U.S. Armed Forces as well as law enforcement and security agencies. Its SuperVision high-definition night vision is designed for commercial and military applications. Employing patented technologies, Xenonics provides innovative solutions for customers who must see farther so they can do their jobs better and safer. Xenonics' products represent the next generation in small, high intensity, high efficiency illumination and low-light vision systems. Visit Xenonics on the web at www.xenonics.com.

Forward-Looking Statements

Except for the historical statements, statements in this release may constitute forward-looking statements within the meaning of section 21E of the Securities Exchange Act of 1934. When used, the words "anticipates," "believes," "expects," "intends," "future," and other similar expressions identify forward-looking statements. These forward-looking statements reflect management's current views with respect to future events and financial performance and are subject to risks and uncertainties, and actual results may differ materially from the outcomes contained in any forward-looking statement. Factors that could cause these forward-looking statements to differ from actual results include delays in development, marketing or sales of new products, and other risks and uncertainties discussed in the company's periodic reports on Form 10-K and 10-Q and other filings with the Securities and Exchange Commission. Xenonics Holdings undertakes no obligation to update or revise any forward-looking statements.

 

XENONICS HOLDINGS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

 

 

 

 

Three months ended

 

Nine months ended

June 30,

 

June 30,

2012

 

2011

 

2012

 

2011

Rounded in thousands, except per share amounts

(unaudited)

 

(unaudited)

 

 

 

 

 

 

 

 

Revenues

$

403,000

 

$

775,000

 

$

1,200,000

 

$

6,323,000

 

 

 

 

 

 

 

 

 

 

Cost of goods sold

 

254,000

 

 

 

537,000

 

 

 

741,000

 

 

 

3,463,000

 

 

 

 

 

 

 

 

 

 

Gross profit

149,000

 

238,000

 

459,000

 

2,860,000

 

 

 

 

 

 

 

 

 

 

Selling, general and administrative

527,000

 

601,000

 

1,587,000

 

1,878,000

 

Research and development

 

191,000

 

 

 

198,000

 

 

 

588,000

 

 

 

495,000

 

 

 

 

 

 

 

 

 

 

Income (loss) from operations

(569,000

)

 

(561,000

)

 

(1,716,000

)

 

487,000

 

 

 

 

 

 

 

 

 

Other income/(expense):

 

 

 

 

 

 

 

 

Interest income

--

 

2,000

 

--

 

5,000

 

Interest (expense)

 

(61,000

)

 

 

(38,000

)

 

 

(139,000

)

 

 

(113,000

)

 

 

 

 

 

 

 

 

 

Income (loss) before

 

 

 

 

 

 

 

provision for income taxes

(630,000

)

 

(597,000

)

 

(1,855,000

)

 

379,000

 

 

 

 

 

 

 

 

 

Income tax provision

 

--

 

 

 

--

 

 

 

2,000

 

 

 

2,000

 

 

 

 

 

 

 

 

 

 

Net income (loss)

$

(630,000

)

 

$

(597,000

)

 

$

(1,857,000

)

 

$

377,000

 

 

 

 

 

 

 

 

 

 

Net income (loss) per share:

 

 

 

 

 

 

 

 

Basic

$

(0.03

)

 

$

(0.02

)

 

$

(0.07

)

 

$

0.02

 

 

Fully-diluted

$

(0.03

)

 

$

(0.02

)

 

$

(0.07

)

 

$

0.02

 

 

 

 

 

 

 

 

 

 

Weighted average shares outstanding:

 

 

 

 

 

 

 

 

Basic

24,976,000

 

25,088,000

 

24,976,000

 

25,107,000

 

Fully-diluted

24,976,000

 

25,088,000

 

24,976,000

 

25,107,000

 
 

XENONICS HOLDINGS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

 

 

 

 

 

June 30,

 

September 30,

 

 

2012

 

2011

Rounded in thousands, except par value

(unaudited)

 

 

 

 

 

 

Assets

 

 

 

 

 

 

 

Current Assets:

 

 

 

 

Cash

$

302,000

 

$

738,000

 

Accounts receivable

325,000

 

273,000

 

Inventories

2,226,000

 

2,542,000

 

Other current assets

 

190,000

 

 

 

144,000

 

 

 

 

 

 

Total Current Assets

3,043,000

 

3,697,000

 

 

 

 

 

 

Equipment, furniture and fixtures, net

17,000

 

35,000

 

Goodwill

375,000

 

375,000

 

Other assets

 

42,000

 

 

 

116,000

 

 

 

 

 

 

Total Assets

$

3,477,000

 

 

$

4,223,000

 

 

 

 

 

 

 

 

 

Liabilities and Shareholders' Equity

 

 

 

 

 

 

 

Current Liabilities:

 

 

 

 

Accounts payable

$

433,000

 

$

414,000

 

Accrued expenses

111,000

 

99,000

 

Accrued payroll and related taxes

84,000

 

96,000

 

Notes payable, net of debt discount

 

1,522,000

 

 

 

--

 

 

 

 

 

 

Total Current Liabilities

2,150,000

 

609,000

 

 

 

 

Notes payable, net of debt discount

 

--

 

 

 

459,000

 

 

 

 

 

 

Total Liabilities

 

2,150,000

 

 

 

1,068,000

 

 

 

 

 

Commitments and contingencies

 

 

 

 

 

 

 

Shareholders' Equity:

 

 

 

 

Preferred shares, $0.001 par value, 5,000,000

 

 

 

 

shares authorized, 0 shares issued and outstanding

--

 

--

 

Common shares, $0.001 par value, 50,000,000

 

 

 

 

shares authorized; 24,976,000 shares issued and

 

 

 

 

outstanding as of June 30, 2012 and September 30, 2011

25,000

 

25,000

 

 

 

 

 

Additional paid-in capital

26,681,000

 

26,652,000

 

 

 

 

 

Accumulated deficit

 

(25,379,000

)

 

 

(23,522,000

)

 

 

 

 

 

Total Shareholders' Equity

 

1,327,000

 

 

 

3,155,000

 

 

 

 

 

 

Total Liabilities and Shareholders' Equity

$

3,477,000

 

 

$

4,223,000

 

Contacts

Investor Contact:
Berkman Associates
310-477-3118
info@BerkmanAssociates.com
or
Company Contact:
Xenonics Holdings, Inc.
Alan Magerman, Chairman
760-477-8900
xenonics@xenonics.com

Release Summary

XENONICS 3Q revenue was $403,000 vs $775,000 in 3Q last year. The net loss was $630,000, or $0.03 per share, vs loss of $597,000, or $0.02 per share in 3Q last year.

Contacts

Investor Contact:
Berkman Associates
310-477-3118
info@BerkmanAssociates.com
or
Company Contact:
Xenonics Holdings, Inc.
Alan Magerman, Chairman
760-477-8900
xenonics@xenonics.com